IDEAYA Biosciences Inc. (NASDAQ:IDYA) saw an upside of 14.60% to $24.80 after adding $3.16 on Wednesday. The 5-day average trading volume is 452,618 shares of the company’s common stock. It has gained $25.15 in the past week and touched a new high 3 times within the past 5 days. An average of 368,429 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 486,220.
IDYA’s 1-month performance is 9.98% or $1.82 on its low of $20.90 reached on 07/27/23. The company’s shares have touched a 52-week low of $9.00 and high of $26.35, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, IDYA has achieved 36.49% or $6.45 and has reached a new high 16 times. However, the current price is down -5.88% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
IDYA stock investors last saw insider trading activity on Jul 10.Throne Jason (Chief Legal Officer) most recently sold 9,485 shares at $23.00 per share on Jul 10. This transaction cost the insider $218,178. Chief Legal Officer, Throne Jason, sold 3,553 shares at a price of $23.02 on Jun 01. Then, on May 31, Chief Legal Officer Throne Jason sold 432 shares at a price of $23.00 per share. This transaction amounted to $9,938.
Valuation Metrics
IDYA stock has a beta of 0.81. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 29.64 while the price-to-book (PB) in the most recent quarter is 3.59.
IDEAYA Biosciences Inc.’s quick ratio for the period ended March 30 was 11.50, with the current ratio over the same period at 11.50. The trailing 12-month EBITDA margin is -118.59%. The firm’s gross profit as reported stood at $113.43 million against revenue of $50.93 million.
Earnings Surprise
For the quarterly period ending March 30 this year, IDEAYA Biosciences Inc.’s cash and short-term investments amounted to $272.23 million against total debt of $3.03 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 40.74% to -$23.64 million, while revenue of -$24.2 million was -2.37% off the previous quarter. Analysts expected IDYA to announce -$0.55 per share in earnings in its latest quarter, but it posted -$0.49, representing a 10.90% surprise. EBITDA for the quarter stood at more than -$27.25 million. IDYA stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 30.94 million, with total debt at $3.03 million. Shareholders hold equity totaling $57.29 million.
Let’s look briefly at IDEAYA Biosciences Inc. (IDYA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 74.34% to suggest the stock is trending Overbought, with historical volatility in this time period at 67.25%.
The stock’s 5-day moving average is $22.31, reflecting a +12.57% or $2.75 change from its current price. IDYA is currently trading +8.79% above its 20-day SMA, +56.22% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +10.80% and SMA200 by+55.53%.
Stochastic %K and %D was 53.45% and 44.45% and the average true range (ATR) pointed at 1.10. The RSI (14) points at 67.07%, while the 14-day stochastic is at 87.53% with the period’s ATR at 1.00. The stock’s 9-day MACD Oscillator is pointing at 0.39 and 0.62 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for IDEAYA Biosciences Inc. (NASDAQ: IDYA), SVB Securities launched coverage with an Outperform rating. Analysts offering their rating for IDYA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate IDYA as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 11 have offered a “buy” rating.
What is IDYA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $24.00 and a high of $40.00, with their median price target at $31.50. Looking at these predictions, the average price target given by analysts is for IDEAYA Biosciences Inc. (IDYA) stock is $32.58.
